Lung Adenocarcinoma — Research

Lung Adenocarcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-13	17,778	`("Adenocarcinoma of Lung"[mh] OR "Adenocarcinoma, Lung"[mh] OR "Adenocarcinomas, Lung"[mh])`	2026-09-13	pubmed
Last 5 years	2021-01-01 → 2026-12-31	7,869	`("Adenocarcinoma of Lung"[mh] OR "Adenocarcinoma, Lung"[mh] OR "Adenocarcinomas, Lung"[mh]) AND (2021/01/01:2026/12/31[dp])`	2026-09-13	pubmed
Last 12 months	2025-09-13 → 2026-09-13	1,393	`("Adenocarcinoma of Lung"[mh] OR "Adenocarcinoma, Lung"[mh] OR "Adenocarcinomas, Lung"[mh]) AND (2025/09/13:2026/09/13[dp])`	2026-09-13	pubmed

Data updated 17 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (98)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 1–25 of 98 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
· Lancet Oncol · 2012 · PMID 22452895 · validated civic_curation pubmed
Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
· Nat Genet · 2014 · PMID 24658004 · validated civic_curation pubmed
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
· J Clin Oncol · 2013 · PMID 23816960 · validated civic_curation pubmed
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.